Mixed backbone antisense oligonucleotides containing 2'-5'-ribon

Details Mixed backbone antisense oligonucleotides containing 2'-5'-ribon Mixed backbone antisense oligonucleotides containing 2'-5'-ribon

1996-09-24

1999-03-23

Knode, Marian C.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 245, 514 44, 435 6, C07H 2102, C07H 2104

Patent

active

058861653

ABSTRACT:
The present invention provides a novel class of oligonucleotides useful for antisense purposes. The oligonucleotides of the invention comprise both deoxyribonucleotides with "natural" 3'-5' internucleotide linkages and ribonucleotides with 2'-5' internucleotide linkages. Because of their conformation structure, oligonucleotides according to the invention possess uniform intra-phosphate distances throughout the oligonucleotide chain, allowing them to bind efficiently to complementary DNA and RNA with "natural" 3'-5' internucleotide linkages. The oligonucleotides according to the invention advantageously exhibit diminished immune stimulation and significantly reduced effect on both complement and coagulation as compared to 3'-5' oligonucleotides.

REFERENCES:
patent: 5149797 (1992-09-01), Pederson et al.
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5521161 (1996-05-01), Malley et al.
patent: 5532130 (1996-07-01), Alul
Agrawal et al.(II), "Mixed-Backbone Oligonucleotides as Second Generation Antisense Oligonucleotides" In Vitro and In Vivo Studies, Proc. Nat. Acad. Sciences USA. 94(6), 2620-2625 (Mar. 18, 1997).
Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research, 5(9), 539-549 (1988).
Gura, "Antisense Has Growing Pains--Efforts to Develop Antisense Compounds for Cancer, AIDS, and Other Diseases Have Encountered Some Unexpected Questions About How the Drugs Really Work," Science, 270, 575-577 (Oct. 27, 1995).
Agrawal and Iyer, Current Opin. Biotech. 6, 12-19 (1995) , Issue No. 4.
Agrawal et al., Biochem. Pharmacol. 50, 571-576 (1995).
Agrawal et al., Proc. Natl. Acad. Sci. USA 85, 7079-7083 (Oct. 1988).
Agrawal et al., Proc. Natl. Acad. Sci. USA 87, 1401-1405 (Feb. 1990).
Agrawal et al., Toxicology Letts. 82/83, 431-434 (1995).
Agrawal, Clin. Pharmacokinet. 28, 7-16 (1995), Issue No. 1.
Agrawal, Trends in Biotechnology 10, 152-158 (May 1992).
Barker et al., Proc. Natl. Acad. Sci. USA 93, 514-518 (Jan. 1996).
Bayever et al., Antisense Res. Dev. 3, 383-390 (1993).
Beaucage, Methods in Molecular Biology, vol. 20, Oligonucleotides and Analogs, pp. 33-62 (S. Agrawal, ed., Humana Press, Totowa, New Jersey), 1993).
Cedergren and Grosjean, Biochem. Cell. Biol. 65, 677-692 (1987).
Crooke et al., Clin. Pharm. Therap. 56, 641-646 (Dec. 1994).
"Dyad's patented oligonucleotides may lead to treatments for male pattern baldness," Biotech Patent News 10(8), 6 (Aug. 1996).
Dougherty et al., J. Am. Chem. Soc. 114, 6254-6255 (1992).
Galbraith et al., Antisense Res. Dev. 4, 201-206 (1994).
Giannaris and Damha, Nucleic Acids Res. 21, 4742-4749 (1993), Issue No. 20.
Hashimoto and Switzer, J. Am. Chem. Soc. 114, 6255-6256 (1992).
Holt et al., Mol. Cell Biol. 8, 963-973, Issue No. 2, Feb. 1988).
Jin et al., Proc. Natl. Acad. Sci. USA 90, 10568-10572 (Nov. 1993).
Kandimalla et al., Nucleic Acids Res. 23, 3578-3584 (1995), Issue No. 17.
Kerr and Brown, Proc. Natl. Acad. Sci. USA 75, 256-260 (Jan. 1978).
Kierzek et al., Nucleic Acids Res. 20, 1685-1690 (1992), Issue No. 7.
Kitajima et al., Science 258, 1792-1795 (Dec. 11, 1992).
Kondo et al., Biochem. 9, 3479-3498 (1970), Issue No. 18.
Krieg et al., Nature 374, 546-549 (Apr. 6, 1995).
Lalitha and Yathindra, Current Sciences 68, 68-75 Issue No. 1 (Jan. 1995).
Lesiak et al., J. Biol. Chem. 258, 13082-13088, Issue No. 21, Nov. 10, 1983.
Matsukura et al., Proc. Natl. Acad. Sci. USA 84, 7706-7710 (Nov. 1987).
Michelson and Monny, Biochim. Biophys. Acta 149, 107-126 (1967).
Nesterova and Cho-Chung, Nature Medicine 1, 528-533, Issue No. 1 (Jun. 1995).
Offensperger et al., EMBO J. 12, 1257-1262 (1993), Issue No. 3.
Padget et al., Science 225, 898-903 (Aug. 31, 1984).
Puglisi and Tinoco, Methods in Enzymology, vol. 180, pp. 304-325 (Dahlberg and Abelson, eds., Academic Press, San Diego, CA) 1989.
Ratajczak et al., Proc. Natl. Acad. Sci. USA 89, 11823-11827 (Dec. 1992).
Sands et al. Mol. Pharmacol. 45, 932-943 (1994).
Sarin et al., Proc. Natl. Acad. Sci. USA 85, 7448-7451 (Oct. 1988).
Sawai et al., J. Biomol. Structure Dyn. 13, 1045-1051 (1996), Issue No. 6.
Schatz et al., EMBO J. 9, 1171-1176 (1990), Issue No. 4.
Seki et al., Nucleic Acids Symp. Series 29, 71-72 (Nov. 9, 1993).
Simons et al., Nature 359, 67-70 (Sep. 3, 1992).
Smith et al., Proc. Natl. Acad. Sci. USA 83, 2787-1791 (May 1986).
Tazawa et al., Biochem. 8, 3499 (1970), Issue No. 18.
Thoung et al., Angew. Chem Int. Ed. Engl. 32, 666-690 (1993).
Ts'o et al., Biochem. 8, 997-1029 (1969), Issue No. 3.
Uhlmann and Peyman, Chem Rev. 90, 543-584, Issue No. 4. (Jun. 1990).
Usher and McHale, Proc. Natl. Acad. Sci. USA 73, 1149-1153 (1976), Issue No. 4 (Apr. 1976).
Westheimer, Acc. Chem. Res. 1, 70-78. (Mar. 1968).
Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75, 280-284, Issue No. 1 (Jan. 1978).
Zhang et al., Biochem. Pharmacol. 49, 929-939 (1995), Issue No. 7.
Zhang et al., Biochem. Pharmacol. 50, 545-556 (1995), Issue No. 4.
Zhang et al., Clin. Pharm. Therap. 58, 44-53, Issue No. 1 (Jul. 1995).
Zhao et al., Biochem. Pharmacol. 51, 173-182 (1996).

Affiliated with

Also associated with

Rating

Mixed backbone antisense oligonucleotides containing 2'-5'-ribon does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mixed backbone antisense oligonucleotides containing 2'-5'-ribon, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mixed backbone antisense oligonucleotides containing 2'-5'-ribon will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2126867